CA2839507A1 - Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators - Google Patents

Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators Download PDF

Info

Publication number
CA2839507A1
CA2839507A1 CA2839507A CA2839507A CA2839507A1 CA 2839507 A1 CA2839507 A1 CA 2839507A1 CA 2839507 A CA2839507 A CA 2839507A CA 2839507 A CA2839507 A CA 2839507A CA 2839507 A1 CA2839507 A1 CA 2839507A1
Authority
CA
Canada
Prior art keywords
oil
vitamin
antigen
catechin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2839507A
Other languages
English (en)
French (fr)
Inventor
Michael Vajdy
Shore Padrah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EPITOGENESIS Inc
Original Assignee
EPITOGENESIS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EPITOGENESIS Inc filed Critical EPITOGENESIS Inc
Publication of CA2839507A1 publication Critical patent/CA2839507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2839507A 2011-06-24 2012-06-22 Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators Abandoned CA2839507A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161500993P 2011-06-24 2011-06-24
US61/500,993 2011-06-24
US201161513840P 2011-08-01 2011-08-01
US61/513,840 2011-08-01
PCT/US2012/043890 WO2012178118A1 (en) 2011-06-24 2012-06-22 Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators

Publications (1)

Publication Number Publication Date
CA2839507A1 true CA2839507A1 (en) 2012-12-27

Family

ID=47422991

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2839507A Abandoned CA2839507A1 (en) 2011-06-24 2012-06-22 Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators

Country Status (8)

Country Link
US (2) US10561720B2 (enExample)
EP (1) EP2723378A4 (enExample)
JP (3) JP6499446B2 (enExample)
CN (2) CN103717235A (enExample)
AU (3) AU2012272652B2 (enExample)
BR (1) BR112013032410A2 (enExample)
CA (1) CA2839507A1 (enExample)
WO (1) WO2012178118A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
JP6499446B2 (ja) * 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
BR112015005921A2 (pt) * 2012-09-21 2017-07-04 Nestec Sa fenóis da planta e seu uso no tratamento ou prevenção de esofagite eosinofílica
CN103961698A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
CL2013001774A1 (es) * 2013-06-18 2014-08-01 Univ Santiago Chile Formulacion con actividad inmunoestimulante/adyuvante que comprende alpinona , dimetil sulfóxido y suero fisiológico; uso de dicha formulación para preparar vacunas para vertebrados.
US9949490B2 (en) 2014-07-02 2018-04-24 Ralco Nutrition, Inc. Agricultural compositions and applications utilizing essential oils
DE202014106007U1 (de) * 2014-07-22 2015-07-23 Bio.Lo.Ga. S.R.L. Zusammensetzung zur Verwendung in der Vorbeugung und Behandlung allergischer Rhinitis
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
PT3209294T (pt) 2014-10-22 2019-10-08 Bio Lo Ga Srl Composição farmacêutica para uso no aumento do trofismo da mucosa nasal
WO2018045174A1 (en) * 2016-08-31 2018-03-08 Baybutt Richard Composition and use thereof
WO2019055513A1 (en) * 2017-09-13 2019-03-21 In Ingredients, Inc. INHIBITED PD-L1 EXPRESSION AND ENHANCED PD-1 EXPRESSION
CN107670032A (zh) * 2017-10-27 2018-02-09 贵州福斯特生物科技有限公司 家禽油乳剂灭活疫苗佐剂及其相应疫苗的制备方法
EP3543698A1 (en) * 2018-03-20 2019-09-25 Helmholtz-Zentrum für Infektionsforschung GmbH Method for determining vaccine efficacy in an individual and means therefore
GB2590272B (en) 2018-07-13 2022-08-31 Council Scient Ind Res Synbiotic composition for improving immune response and antioxidant capacity during aging and a process for the preparation thereof
KR20200114310A (ko) * 2019-03-28 2020-10-07 연세대학교 산학협력단 녹차 유래 성분을 함유하는 바이러스 백신용 면역증강제 조성물
CN111067915A (zh) * 2020-01-09 2020-04-28 昆明医科大学 老鹳草素在制备用于治疗维生素d不足和/或缺乏疾病的药物中的用途
US20210337810A1 (en) * 2020-04-30 2021-11-04 Environmental Services Pty Ltd Compositions for improving agricultural production
US20210346340A1 (en) * 2020-05-07 2021-11-11 EpitoGenesis, Inc. Pharmaceutical Compositions, Comprising a Combination of Select Carriers and Flavonoids as Antipathogens

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216201A (en) * 1978-05-22 1980-08-05 Germaine Monteil Cosmetiques Corp. Cosmetic emulsion compositions having skin moisturizing properties
DE3241113A1 (de) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen Vakzinen mit zuschlagstoffen
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
DK0750907T3 (da) * 1995-06-30 2002-07-08 American Cyanamid Co Stabile vaccinepræparater til parenteral administrering, en fremgangsmåde til deres anvendelse og en fremgangsmåde til deres fremstilling
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6761914B2 (en) 1997-05-27 2004-07-13 Sembiosys Genetics Inc. Immunogenic formulations comprising oil bodies
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
BR9814912A (pt) 1997-11-28 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
CA2318345C (en) * 1997-12-24 2011-06-07 Shaklee Corporation Composition with high efficiency skin protection from damaging effects of ultraviolet light
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CN1338005A (zh) 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOMIC SEQUENCE OF CHLAMYDIA PNEUMONIAE
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
DE19935763B4 (de) * 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
US20040081654A1 (en) 2000-06-16 2004-04-29 Schryvers Anthony B Use of plant oil-bodies in vaccine delivery systems
ATE440861T1 (de) * 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
KR20020024994A (ko) * 2000-09-27 2002-04-03 원인호 영양비누물질의 조성과 금은 비누의 제조
EP1228769A1 (de) * 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
FR2823119B1 (fr) 2001-04-05 2004-02-20 Seppic Sa Adjuvant d'immunite contenant un cation metallique complexe et vaccin le contenant
DK1997498T3 (da) * 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
GB0216371D0 (en) 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
JP4456334B2 (ja) * 2003-02-14 2010-04-28 高砂香料工業株式会社 メラニン生成抑制剤及びそれを含有する皮膚外用剤
WO2005094770A1 (en) 2004-03-30 2005-10-13 Unilever Plc Skin lightening compositions comprising vitamines and flavonoids
US8541167B2 (en) * 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
JP2006028148A (ja) * 2004-07-14 2006-02-02 Omori Kitaro 外用組成物
US7544816B2 (en) 2004-08-19 2009-06-09 The Hong Kong Polytechnic University (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
JP2006206539A (ja) 2005-01-31 2006-08-10 Biseibutsu Kagaku Kenkyusho:Kk アジュバント及びこれを用いたワクチン
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US20070082073A1 (en) 2005-05-18 2007-04-12 University Of South Florida Catechin Adjuvants
WO2007060174A1 (en) * 2005-11-23 2007-05-31 Nestec S.A. Oil-in-water emulsion for creating new product consistencies
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
JP2010507361A (ja) * 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
US20080254188A1 (en) 2007-02-01 2008-10-16 National Research Council Of Canada Formulations of lipophilic bioactive molecules
JP2009165450A (ja) 2008-01-11 2009-07-30 Otsuka Yakuhin Kogyo Kk 赤飯用改良剤および、その改良剤を用いた赤飯の製造方法
EP2278997B1 (en) * 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
EP2305742B1 (en) 2009-10-01 2017-02-22 Symrise AG Spherical core-shell-particle
JP2011105652A (ja) 2009-11-18 2011-06-02 Oriza Yuka Kk 美肌用組成物
JP6499446B2 (ja) * 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物

Also Published As

Publication number Publication date
AU2012272652A1 (en) 2014-01-16
AU2019202405A1 (en) 2019-05-02
CN103717235A (zh) 2014-04-09
US20240082381A1 (en) 2024-03-14
CN107837394A (zh) 2018-03-27
WO2012178118A1 (en) 2012-12-27
AU2012272652B2 (en) 2017-06-01
US20130028961A1 (en) 2013-01-31
JP2018065825A (ja) 2018-04-26
BR112013032410A2 (pt) 2017-01-17
AU2019202405B2 (en) 2020-12-24
EP2723378A4 (en) 2015-01-28
JP2020002158A (ja) 2020-01-09
EP2723378A1 (en) 2014-04-30
AU2017221829A1 (en) 2017-09-21
US10561720B2 (en) 2020-02-18
JP2014531396A (ja) 2014-11-27
JP6499446B2 (ja) 2019-04-10

Similar Documents

Publication Publication Date Title
US20240082381A1 (en) Pharmaceutical compositions, comprising of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CA2748788C (en) The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
Bastola et al. Vaccine adjuvants: smart components to boost the immune system
US20070166800A1 (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
Xu et al. Immunogenicity of antigen adjuvanted with AS04 and its deposition in the upper respiratory tract after intranasal administration
Zhao et al. Immunological adjuvant efficacy of glycyrrhetinic acid liposome against Newcastle disease vaccine
US20240050399A1 (en) Pharmaceutical compositions, comprising a combination of select carriers and flavonoids as antipathogens
AU2015268780B2 (en) Adjuvant compositions and methods of use
Banerjee et al. Advancements in adjuvanticity of bioactive inorganic and organic compounds
Boulikas et al. Can we make our vaccines safer?
MX2008008966A (en) Immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170519

FZDC Discontinued application reinstated

Effective date: 20200117

FZDE Discontinued

Effective date: 20211224